Arecent clinical study in the United States on selenium replete subjects further established the bioavailability and safety of Selenium SeLECT. Subjects were grouped to receive either selenomethionine, high-selenium yeast or sodium selenite in moderate to high doses. The effect on urinary excretion of selenium biomarkers was measured by after 16 weeks of supplementation. "Effects of Chemical Form of Selenium on Plasma Biomarkers in a High-Dose Human Supplementation Trial" published in the April 2006 edition of Cancer Epidemiology, Biomarkers & Prevention, a journal distributed by the American Association for Cancer Research, found that bioavailability of selenium was greatest for selenomethionine (as Selenium SeLECT from Sabinsa Corporation), less for highselenium yeast and the least for sodium selenite.
As summarized by Vladimir Badmaev, M.D., Ph.D., vice president of scientific and medical affairs, Sabinsa Corporation: "This study further substantiates the fact that selenium in the form of selenomethionine, specifically our Selenium SeLECT compound, is more available to be absorbed and used by the body. Additionally, some of the participants had total daily intakes of more than 800 micrograms of selenium over the course of the study and showed no signs of selenium toxicity despite the fact that 800 micrograms is well above the recognized safe upper limit set by the Institute of Medicine."
